__NUXT_JSONP__("/drugs/Quizartinib", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"950769-58-1",chebiId:"",chemicalFormula:"C29H32N6O4S",definition:"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3\u002FSTK1), colony-stimulating factor 1 receptor (CSF1R\u002FFMS), stem cell factor receptor (SCFR\u002FKIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.",fdaUniiCode:"7LA4O6Q0D3",identifier:"C68936",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1967"],synonyms:["(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide","AC-220","AC010220","AC220","N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea","QUIZARTINIB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FQuizartinib",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Quizartinib","2021-10-30T13:43:21.913Z")));